Compare ZNTL & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZNTL | SAR |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 233.9M |
| IPO Year | 2020 | 2006 |
| Metric | ZNTL | SAR |
|---|---|---|
| Price | $2.21 | $13.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | $7.44 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.3M | 163.5K |
| Earning Date | 11-09-2026 | 10-06-2026 |
| Dividend Yield | N/A | ★ 21.64% |
| EPS Growth | ★ 18.03 | 14.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.78 |
| Revenue Next Year | N/A | $6.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.21 | $13.52 |
| 52 Week High | $6.95 | $24.07 |
| Indicator | ZNTL | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 22.01 |
| Support Level | $2.09 | N/A |
| Resistance Level | $2.76 | $23.85 |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 17.35 | 7.07 |
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.